Immunai Stock

HealthTech

Looking to sell Immunai stock or options?

Founded: 2018Funding to Date: $295M

Immunai, a developer of immune system technology, is aimed at providing treatments for oncology and auto-immune disorders. The company's platform merges comprehensive mapping and reprogramming of the immune system with single-cell biology, AI, and machine learning. This provides novel insights into the immune system and enables healthcare researchers to speed up drug development and enhance patient outcomes.

Investors Include:

Meron Capital, 8VC, Alexandria Venture Investments, Gefen Capital, Perot Jain, Dexcel Pharma, Piedmont Capital Investments, Talos Ventures, Duquesne Family Office, iAngels, TLV Partners, Schusterman Family Investments, ICON (Palo Alto), R-Squared Ventures, Koch Disruptive Technologies, Gad Allon, Piedmont, Viola Ventures, Catalio Capital Management.

Looking to sell Immunai Stock or Options?

We have an even better solution: The Collective Exchange Fund

Get in touch and see if we can help you